BioCentury
ARTICLE | Clinical News

Milatuzumab: Phase I/II data

December 13, 2010 8:00 AM UTC

An ongoing, open-label, dose-escalation, U.S. Phase I/II trial in 9 evaluable patients showed that milatuzumab in combination with veltuzumab produced 4 objective responses. Dose-escalation has reach...